Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations  by Kreiss, A. et al.
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a  b  s  t  r  a  c  t
Tasmanian  devils  (Sarcophilus  harrisii)  risk  extinction  from  a contagious  cancer,  devil  facial  tumour  dis-
ease  (DFTD)  in  which  the  infectious  agent  is  the  tumor  cell  itself.  Because  devils  are  unable  to  produce
an  immune  response  against  the  tumor  cells no  devil  has  survived  ‘infection’.  To  promote  an  immune
response  we  immunized  healthy  devils  with  killed  DFTD  tumor  cells  in  the  presence  of  adjuvants.  Immune
responses,  including  cytotoxicity  and  antibody  production,  were  detected  in ﬁve of  the  six  devils.  The
incorporation  of  adjuvants  that  act via  toll  like receptors  may  provide  additional  signals  to break  ‘immuno-
logical  ignorance’.  One  of  these  devils  was  protected  against  a challenge  with  viable  DFTD  cells.  This  was
a short-term  protection  as  re-challenge  one  year  later  resulted  in  tumor  growth.  These results  suggestevil facial tumor disease (DFTD)
ransmissible cancer
ontanide
LISA
low cytometry
that Tasmanian  devils  can  generate  immune  responses  against  DFTD  cells.  With  further  optimization  of
immune  stimulation  it should  be possible  to protect  Tasmanian  devils  against  DFTD  with  an  injectable
vaccine.
Crown  Copyright  © 2015  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).eterinary immunology
arsupial
. Introduction
Devil Facial Tumour Disease (DFTD) is a clonal [1] and fatal
ransmissible cancer that arose in a single female Tasmanian devil
Sarcophilus harrisii), prior to 1996 [2,3]. It has been spread by bit-
ng [2] and killed more than 80% of devils in the island state of
asmania. Extinction is possible [4].
DFTD is a cancer of Schwann cells [5]. Initially it was believed
hat a lack of genetic diversity accounted for why the tumor cells
ere not immunologically rejected [6]. More recently it has been
dentiﬁed that DFTD cells do not express surface class I Major His-
ocompatibility Complex molecules [7] and are therefore ignored
y the host immune system. DFTD progresses with no sign of
eukocyte inﬁltration [8,9]. There is no, or limited, evidence for
∗ Corresponding author at: Menzies Institute for Medical Research, University of
asmania, Private Bag 23, Tasmania 7000, Australia. Tel.: +61 03 6226 4832.
E-mail addresses: Alexandre.Kreiss@utas.edu.au (A. Kreiss),
abby.Brown@dhhs.tas.gov.au (G.K. Brown), Cesar.Tovar@utas.edu.au (C. Tovar),
ruce.Lyons@utas.edu.au (A.B. Lyons), G.M.Woods@utas.edu.au (G.M. Woods).
1 Current address: Department of Health and Human Services, Tasmania,
ustralia.
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.039
264-410X/Crown Copyright © 2015 Published by Elsevier Ltd. This is an open acces
y-nc-nd/4.0/).any devils recovering from DFTD [10,11]. This suggests the tumor
cells are not rejected as a typical allograft, even though devils have
robust humoral and cell mediated immune responses [9,12–14].
Skin allografts can be rejected, exhibiting CD8+ T cell inﬁltration
and xenogeneic tumor cells can be killed via antibody dependent
cytotoxicity, a property of NK cells [14,15]. Preliminary experi-
ments with two devils immunized with DFTD cells failed to detect
an immune response in either devil [15]. Since then we  have
shown that in mice DFTD cells are immunogenic and that sonicated,
freeze/thawed and irradiated cells can induce immune responses
[16]. As a prelude toward the development of a vaccine, the objec-
tive of this study was to further investigate if an immune response
could be generated against DFTD cells.
Tasmanian devils are an endangered species and access to ani-
mals for research purposes was limited. This restricted sample size
and the capacity to incorporate a diverse range of vaccine formu-
lations. We  hypothesized that there is sufﬁcient genetic difference
between DFTD cells and host devils for an immune response to be
induced. This could be promoted in the presence of adjuvants. We
used Montanide and CpG. Montanide, is a proprietary water in oil
adjuvant (Seppic S.A., France) that has been shown to enhance both
cellular and humoral immunity in humans [17–20]. CpG included
the oligonucleotides CpG1668 and CpG1585, as they increase the
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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ffectiveness of standard adjuvants [21–26]. They act via Toll-like
eceptor 9 (TLR9) and have been used successfully with tumor
ntigens in Montanide ISA51 [21,27].
The principle aim of this study was to provide evidence that,
n the presence of adjuvants, cultured DFTD cell preparations that
ere inactivated by either -irradiation, sonication, or repeated
reeze thawing could induce humoral or cytotoxic responses in
asmanian devils.
. Methods
.1. DFTD cell lines
The DFTD cell lines ½Pea, 2112 (both strain 2) and C5065 (strain
) [1,28] were maintained in complete RPMI medium, which was
PMI 1640 medium (Life Technologies, Grand Island, USA) supple-
ented with 10% vol/vol heat inactivated fetal calf serum (Bovogen
iological, Victoria, Australia), 5 mM l-glutamine (Sigma–Aldrich,
t. Louis, USA) and 100 IU of gentamicin sulfate (Pﬁzer, Western
ustralia, Australia) at 35 ◦C in a humidiﬁed atmosphere of 5% CO2
n air.
.2. Tasmanian devils
The care of Tasmanian devils was in accordance with Depart-
ent of Primary Industries, Parks, Water and Environment of
asmania guidelines. Their endangered status limited access. All
evils were adults and their ages ranged from two  to four years
t commencement. There was a mixture of males and females.
he University of Tasmania Animal Ethics Committee approved
ll procedures under permit numbers A9215 and A11436. Blood
ollection, immunization and live cell challenges were performed
nder anesthesia induced with 5% Isoﬂuorane® (Abbot Australasia
ty Ltd., Botany, Australia) reducing to 3% via a mask.
.3. Preparation of DFTD cells for immunization
Vaccines consisted of 108 inactivated DFTD tumor cells. The
evils TD1 and TD2 received an equal mixture of the strain 2
ell lines ½ Pea and 2112. All other devils (including TD2 on re-
mmunization) received the strain 3 cell line C5065. As this cell
ine labeled with Cr51, it was suitable for cytotoxicity assays. They
ere either freeze/thawed (six to eight quick cycles of freezing in
iquid nitrogen and thawing in a 37 ◦C water bath), irradiated (20
ray of  radiation using a Varian Clinac 23-EX linear accelerator
Varian Medical Systems Inc., California, USA), or sonicated (dis-
uption with four ultra-sonic cycles of 60 s at input 6, Microson
L-2000 ultrasonic cell disruptor, VWR  International, Radnor, USA)
able 1
ummary of DFTD immunizations, challenges and tumor development. (2015) 3016–3025 3017
with 60 s intervals on ice. For all preparations, lack of cell viability
was conﬁrmed using trypan blue dye and cell culture. Cell prepara-
tions in 1000 L of sterile PBS were vigorously mixed with 300 L
of Montanide ISA71VG adjuvant (Seppic S.A., France) and, with the
exception of frozen/thawed cells, 200 L (200 g) of CpG was also
included. The mixture was vigorously mixed and kept on ice until
required. The initial immunizations of TD1 and TD2 were at closer
time intervals than the other devils. After these ﬁrst two devils it
was deemed more appropriate (ethically and biologically) to space
the immunizations further apart.
2.4. Immunizations, blood collection and live DFTD cell challenge
Immunizations were subcutaneous injections with a 21 gauge
needle into the rump (schedule summarized in Table 1). Previously
we used the shoulder [15] but the rump is a more convenient site
to monitor for signs of inﬂammation and the unlikely possibility
of tumor growth. Due to limited availability of devils, individual
animals were assessed rather than groups. The different vaccine
compositions were chosen to maximize the number of combina-
tions. Before and 14 days after each immunization approximately
12 ml  of blood was collected from the jugular vein. Up to 4 ml of
blood was  placed into clot activating tubes (Greiner Bio-one, Frick-
enhausen, Germany) for serum analyses and the remainder into
lithium heparin anticoagulant tubes (BD Biosciences, NJ, USA) for
cell analyses.
Due to ethical considerations, it was  only possible to challenge
two devils. Both were initially challenged with strain 2 DFTD cells.
TD1 did not produce an immune response and was  not boosted
prior to the challenge. Effectively this devil served as a ‘control’
for tumor growth. TD2 produced an immune response and was
boosted prior to challenge. This devil was the ‘test’ for protection
against tumor growth. 25,000 viable tumor cells in 500 L of PBS
were injected in two  sites; subcutaneous tissue of the right cheek
and oral mucosa of the left lower jaw. This dose was selected as
balance between the number of cells transmitted during natural
transmission and a dose that would not be large enough to over-
whelm the immune response. These sites were selected to reﬂect
the most common sites that DFTD develops in wild devils. The devils
were examined monthly under anesthesia for evidence of tumors.
A second challenge took place in one of these devils. Again with
25,000 viable tumor cells, but this time with strain 3 DFTD cells
and on the left and right subcutaneous tissue of the cheeks. The
oral mucosa was not used as it was difﬁcult to determine when
tumors appeared, it caused inconvenience to the devil and could
not be surgically removed.
Table 1 summarizes the immunization preparation, adjuvants,
immunization times and challenges of devils.
3018 A. Kreiss et al. / Vaccine 33 (2015) 3016–3025
Fig. 1. Antibody responses and DFTD tumor development of devils that received frozen/thawed cells plus Montanide ISA71MVG. (a) and (c) Flow cytometry. Evidence for
antibodies in TD2: (b) and (d) ELISA. Evidence for low levels of antibodies in TD1, but higher levels in TD2. (NS) Not signiﬁcantly different to pre-immune, (+) Signiﬁcantly
different to pre-immune and relative light unit intensity of 1:5000 dilution up to twice as high as pre-immune, (++) Signiﬁcantly different to pre-immune and relative light
unit  intensity of 1:5000 dilution 2–4 times higher than pre-immune, (+++) Signiﬁcantly different to pre-immune and relative light unit intensity of 1:5000 dilution more
than  4 times higher than pre immune: (e) Western blot. Evidence for DFTD speciﬁc antibodies in TD2.
ine 33
2
m
H
i
2
c
5
r
n
r
C
C
2
i
9
t
(
t
o
i
g
d
2
(
C
c
b
2
W
o
R
P
(
p
D
w
a
u
1
o
D
t
p
w
4
C
a
t
e
i
P
2
oA. Kreiss et al. / Vacc
.5. Cytotoxicity assays
A radioactive chromium (51Cr) release assay was used [15]. Devil
ononuclear cells were obtained by gradient centrifugation over
istopaque 1077 (Sigma–Aldrich, St. Louis, USA) and resuspended
n complete RPMI medium. DFTD cells were labeled with 51Cr for
 h and added to triplicate wells of a round bottom 96 well plate
ontaining devil mononuclear cells. After incubation at 37 ◦C with
% CO2 in air for 18 h, culture supernatants were analyzed for 
adioactivity using a Genesys  radiation counter (Laboratory Tech-
ologies Inc., IL, USA). Mean percent cytotoxicity values at each
atio were calculated thus:
Percent cytotoxicity = ((sample CPM − mean negative control
PM)/(mean maximum control CPM − mean negative control
PM)) × 100 (%).
.6. Antibody measurement by ﬂow cytometry
Washed DFTD tumor cells (100 L at 106/mL  diluted in wash-
ng buffer – 1% BSA in PBS) were placed in wells of a round bottom
6 well plate on ice. Serum samples were diluted 1:100 (ﬁnal dilu-
ion 1:200) with washing buffer, mixed with C5065 tumor cells
strain 3) and incubated on ice for 30 min. Cells were washed
wice with washing buffer, and incubated with 50 L of 2 g/mL
f a monoclonal mouse anti-devil IgG [29] for 30 min, washed and
ncubated with 50 L of 0.2 g/mL of alexa ﬂuor 488-conjugated
oat anti-mouse IgG antibody for 30 min  (Molecular Probes, Lei-
en, The Netherlands). After washing, cells were resuspended in
00 L of washing buffer containing 3 M of propidium iodide
Sigma–Aldrich, St. Louis, USA). Viable cells were analyzed on a BD
anto II ﬂow cytometer (Becton Dickinson, New Jersey, USA). The
ontrols (DFTD cells labeled with the secondary and tertiary anti-
odies, but no devil serum) did not show background ﬂuorescence.
.7. Antibody measurement by ELISA
White opaque 96-well plates (ThermoFisher Scientiﬁc,
altham, USA) were coated overnight at 4 ◦C with 10 g/mL
f DFTD protein extracted from cultured DFTD tumor cells using
IPA buffer (Thermo Scientiﬁc, Rockford, IL) and diluted in
BS. Wells were washed three times with 0.05% of Tween 20
Sigma-Aldrich, St. Louis, USA) in PBS (PBS-T) and non-speciﬁc
rotein binding was blocked with protein blocker (Dako, Glostrup,
enmark). After three washes with PBS-T, 100 L of serum samples
ere serial diluted in PBS in triplicate wells, incubated overnight
t 4 ◦C, washed three times with PBS-T and 100 L of 2 g/mL of
nconjugated mouse anti-devil IgG [29] added and incubated for
 h at room temperature. After three washes with PBS-T, 100 L
f 0.05 ng/mL of HRP goat anti-mouse antibody (Dako, Glostrup,
enmark) was placed in each well, incubated for 1 h and washed
hree times with PBS-T. 100 L per well of chemiluminescent
eroxidase substrate for ELISA (Sigma–Aldrich, St. Louis, USA)
as added for 1 min  and relative light units (RLUs) measured at
25 nm (SpectraMax M2,  Molecular Devices, Sunnyvale, USA).
ontrols consisting of wells with no protein, no serum or no mouse
nti-devil IgG did not bind non-speciﬁcally. All experiments with
he tested samples were performed at least twice. Results are
xpressed as units of light at all dilutions.
Statistics to compare pre-immune with immune samples of
ndividual devils were performed with two-way ANOVA (Graph-
adPrism)..8. Western blot
Total cell protein from a DFTD cell line was extracted with 1 ml
f RIPA buffer (Thermo Scientiﬁc, Rockford, IL) containing 10 l (2015) 3016–3025 3019
of HALTTM protease inhibitor cocktail (Thermo Scientiﬁc, Rock-
ford, USA) for approximately 40 mg  of cell pellet. The sample was
sonicated, centrifuged at 16,000 × g for 20 min  at 4 ◦C and the super-
natant transferred to a new tube for protein quantiﬁcation (EZQTM
Protein Quantitation Kit, Life Technologies, Eugene, USA). 20 g of
protein sample was added to BoltTM LDS Sample Buffer (4×)  (Life
Technologies, Carlsbad, USA) and BoltTM Sample Reducing Agent
(10×) with the remaining volume made up by Milli-Q water to
10 l. The samples were vortexed, centrifuged and heated at 70 ◦C
for 10 min. Samples and a molecular weight marker were loaded
on Bolt® 4–12% Bis-Tris Plus mini-gels. The gels were run at 165 V
for 50 min  using BoltTM MES  SDS running buffer and the Bolt® mini
gel tank.
Electroblotting was  performed using the iBlot® dry blotting
system using 20 V for 7.5 min  (Life Technologies, Carlsbad, USA).
Membranes were incubated overnight at 4 ◦C with an animal
protein-free blocker buffer (Vector Laboratories, Burlingame, USA)
in TBS containing 0.05% tween (TBS-T). Membranes were incubated
for 2 h with pre-immune and immune serum from two  immu-
nized devils (TD1 and TD2) at a dilution of 1:125 in blocking
buffer. Negative controls were no devil serum and no serum plus
no secondary antibody. After four washes with TBS-T, 2 g/mL of
unconjugated mouse anti-devil IgG was  applied for 1 h, followed
by four washes and incubation with 0.05 ng/mL of HRP goat anti-
mouse antibody (Dako, Glostrup, Denmark). Chemiluminescence
detection was performed with ImmobilonTM Western HRP sub-
strate (Millipore, Billerica, USA) for 5 min  and imaged using the
Image Station 4000MM Pro system (Carestream Health, Wood-
bridge, USA).
3. Results
3.1. Immunization with frozen/thawed DFTD cells in Montanide
adjuvant
3.1.1. Antibody responses
TD1 had negligible anti-DFTD antibody responses by ﬂow
cytometry, but there was a small increase in antibodies by ELISA
14 and 42 days after the ﬁrst immunization, but this did not persist
(Fig. 1a and b). TD2 showed evidence for DFTD speciﬁc antibodies
by ﬂow cytometry and ELISA (Fig. 1c and d).
3.1.2. Western blot
To conﬁrm that the antibody responses from TD2 were DFTD
speciﬁc, western blots were performed (Fig. 1e). The immune
serum of TD2 showed reactivity, especially 14 days after the ﬁrst
immunization. This coincided with the highest ﬂow cytometric
response. In contrast no obvious bands were produced with the
immune serum of TD1.
3.1.3. Cytotoxic responses
A DFTD cell line that labeled sufﬁciently with Cr51 was not avail-
able at the time TD1 and TD2 were ﬁrst tested.
3.1.4. Challenge with live tumor cells
Both devils were challenged with live DFTD tumor cells. TD1
developed tumors at both sites, 84 days after the challenge. The
tumor stained positively with periaxin, a marker for DFTD cells.
126 days after tumor development the cheek tumor was surgically
removed due to its large size. For ethical reasons TD1 was euth-
anized 56 days after removal. There was evidence for metastases
only in the right submandibular lymph node. TD2 did not develop
palpable tumors on either site for 190 days. To determine whether
the protection was long-term, a second challenge was carried
out, at Day 476. Small sized tumors (less than 1 cm in diameter)
were detected in both challenged sites 154 days after the second
3020 A. Kreiss et al. / Vaccine 33 (2015) 3016–3025
Table 2
Summary of immune responses generated for all Tasmanian devils.
Devil Immunization Analysis Antibody response Cytotoxicity
Flow cytometry ELISA Chromium release assay
TD1 Frozen/thawed + Montanide
Day 0
Day 7
Day 14 Day 14 − + ND
Day 42 − + ND
Day  70 Day 84 − NS ND
Challenge Day 287 Tumor developed 84 days later
TD2  1st test Thawed/frozen cells + Montanide
Day 0
Day 7
Day 14 Day 14 +++ ++ ND
Day 42 ++ ++ ND
Day  70 Day 84 ++ +++ ND
Day  217
First challenge Day 287 No tumor development
Second challenge Day 476 Tumor developed 154 days later
TD2  2nd test Sonicated cells + Montanide + CpG1668
Day 0 (day 1127) Day 14 + +++ +++
Day  28 Day 42 + +++ +++
Day  56 Day 70 − +++ ND
TD3  Irradiated cells + Montanide + CpG1668
Day 0 Day 14 − NS ++
Day  28 Day 42 − + NS
Day  56 Day 70 ND ND ND
TD4  1st test Irradiated cells + Montanide + CpG1668
Day 0 Day 14 − ++ +++
Day  28 Day 42 − + +++
Day  56 Day 70 +++ ++ +++
TD4  2nd test Sonicated cells + Montanide + CpG1668
Day 0 (day 162) Day 14 + +++ +++
Day  28 Day 42 + +++ ++
Day  56 Day 70 − +++ ND
TD5  Irradiated cells + Montanide + CpG1585
Day 0 Day 14 − NS +
Day  28 Day 42 − NS +
Day  56 Day 70 + ++ NS
TD  6 Irradiated cells + Montanide + CpG1585
Day 0 Day 14 − NS ++
Day  28 Day 42 − NS +
Day  56 Day 70 − NS NS
Flow cytometry assay: (−) Median ﬂuorescence intensity (MFI) not higher than pre-immune, (+) MFI up to twice as high as pre-immune, (++) MFI  2 to 4 times higher than
pre-immune, (+++) MFI  above 4 times higher than pre-immune. ELISA: (NS) Not signiﬁcantly different to pre-immune, (+) Signiﬁcantly different to pre-immune and relative
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hromium release assay: (NS) Not signiﬁcantly different to pre-immune, (+) Signiﬁ
ifferent to pre-immune and between 21 and 30% cytotoxicity, (+++) Signiﬁcantly d
hallenge (Table 2). The tumors were conﬁrmed to be DFTD as
escribed above and wide margin excision surgery was  performed
o remove the tumors. As there was no recurrence after one year,
his was regarded as a surgical ‘cure’, and the devil was included
n further experiments, 490 days after the surgery.
.2. Devils immunized with irradiated DFTD cells in Montanide
djuvant with CpG 1668 oligonucleotides
.2.1. Antibody responses
TD3 showed evidence for low levels of anti-DFTD antibodies at
ay 42, but this was only evident with the ELISA (Fig. 2a and c). TD4
ad anti-DFTD antibody responses, which were evident with ELISA
nd ﬂow cytometry. The responses were highest at day 70, which
as 14 days after the third immunization (Fig. 2d and e)..2.2. Cytotoxic responses
The pre-immune responses from TD3 and TD4 were usually
elow 10% cytotoxicity; hence 10% was considered the cut-off. TD3y different to pre-immune and relative light unit intensity of 1:5000 dilution 2 to 4
light unit intensity of 1:5000 dilution more than 4 times higher than pre-immune.
 different to pre-immune and between 11 and 20% cytotoxicity, (++) Signiﬁcantly
nt to pre-immune and greater than 30% cytotoxicity. ND: not done.
showed evidence for cytotoxicity 14 days after the ﬁrst immuniza-
tion, but this had subsided by day 42 (Fig. 2c). TD4 had consistent
responses, with cytotoxicity above 30% after each of the immuniza-
tions. The highest was  43% after the third and ﬁnal immunization
(Fig. 2f).
3.3. Devils immunized with irradiated DFTD cells in Montanide
adjuvant with CpG 1585 oligonucleotides
3.3.1. Antibody responses
TD5 had undetectable anti-DFTD antibodies after the ﬁrst two
immunizations (days 14 and 42), but antibody was detected after
the third immunization (day 70) (Fig. 3a and b). TD6 had no
detectable anti-DFTD antibody responses (Fig. 2d and e).3.3.2. Cytotoxic responses
Although both devils had the highest responses 14 days after the
ﬁrst immunization, neither devil provided convincing evidence for
cytotoxicity (Fig. 3c and f).
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Fig. 2. Antibody and cytotoxic responses of devils that received irradiated cells, Montanide ISA71MVG and CpG1668. (a) and (d) Flow cytometry assay. Evidence for antibodies
in  TD4 (but not TD3), but only after 70 days: (b) and (e) ELISA. Evidence for low levels of antibodies in TD3, but only after 42 days and evidence for antibodies in TD4 from
14  days: (NS) Not signiﬁcantly different to pre-immune, (+) Signiﬁcantly different to pre-immune and relative light unit intensity of 1:5000 dilution up to twice as high as
pre-immune, (++) Signiﬁcantly different to pre-immune and relative light unit intensity of 1:5000 dilution 2 to 4 times higher than pre-immune, (+++) Signiﬁcantly different
to  pre-immune and relative light unit intensity of 1:5000 dilution more than 4 times higher than pre immune: (c) and (f) Chromium release assay. Evidence for cytotoxicity
in  TD3 after 14 days, but not after 42 days and in TD4 after all timepoints. (NS) Not signiﬁcantly different to pre-immune, (+) Signiﬁcantly different to pre-immune and
between 11 and 20% cytotoxicity, (++) Signiﬁcantly different to pre-immune and between 21 and 30% cytotoxicity, (+++) Signiﬁcantly different to pre-immune and greater
than  30% cytotoxicity.
3022 A. Kreiss et al. / Vaccine 33 (2015) 3016–3025
Fig. 3. Antibody and cytotoxic responses of devils that received irradiated cells, Montanide ISA71MVG and CpG1585. (a) and (d) Flow cytometry assay. Evidence for antibodies
in  TD5 (but not TD6) but only after 70 days: (b) and (e) ELISA. Evidence for low levels of antibodies in TD5, but only after 70 days and no evidence for antibodies in TD6. (NS)
Not  signiﬁcantly different to pre-immune, (+) Signiﬁcantly different to pre-immune and relative light unit intensity of 1:5000 dilution up to twice as high as pre-immune, (++)
S ution 
a re imm
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tigniﬁcantly different to pre-immune and relative light unit intensity of 1:5000 dil
nd  relative light unit intensity of 1:5000 dilution more than 4 times higher than p
fter  14 and 42 days, but not after 70 days. (NS) Not signiﬁcantly different to pre-i
++)  Signiﬁcantly different to pre-immune and between 21 and 30% cytotoxicity, (+
.4. Devils immunized with sonicated DFTD cells in Montanide
djuvant with CpG 1668 oligonucleotidesThese two devils had been immunized previously (896 days
reviously for TD2 and 92 days previously for TD4). At the
ime of ‘re-testing’ the anti-DFTD antibody and cytotoxicity2 to 4 times higher than pre-immune, (+++) Signiﬁcantly different to pre-immune
une. (c) and (f) Chromium release assay. Evidence for cytotoxicity in TD5 and TD6
e, (+) Signiﬁcantly different to pre-immune and between 11 and 20% cytotoxicity,
gniﬁcantly different to pre-immune and greater than 30% cytotoxicity.
levels were very low and considered equivalent to pre-immune
serum.3.4.1. Antibody responses
TD2 and TD4 showed similar responses following ‘re-
immunization’. Flow cytometry detected low levels of anti-DFTD
A. Kreiss et al. / Vaccine 33 (2015) 3016–3025 3023
Fig. 4. Antibody and cytotoxic responses of devils that received sonicated cells, Montanide ISA71MVG and CpG1668. (a) and (d) Flow cytometry assay. Evidence for low levels
of  antibodies in TD2 and TD4 after 14 and 42 days but not after 70 days: (b) and (e) ELISA. Evidence for antibodies in TD2 and TD4 at all timepoints. (NS) Not signiﬁcantly
different to pre-immune, (+) Signiﬁcantly different to pre-immune and relative light unit intensity of 1:5000 dilution up to twice as high as pre-immune, (++) Signiﬁcantly
different to pre-immune and relative light unit intensity of 1:5000 dilution 2 to 4 times higher than pre-immune, (+++) Signiﬁcantly different to pre-immune and relative
light  unit intensity of 1:5000 dilution more than 4 times higher than pre immune. (c) and (f) Chromium release assay. Evidence for cytotoxicity in TD2 and TD4 after 14
and  42 days. (NS) Not signiﬁcantly different to pre-immune, (+) Signiﬁcantly different to pre-immune and between 11 and 20% cytotoxicity, (++) Signiﬁcantly different to
pre-immune and between 21 and 30% cytotoxicity, (+++) Signiﬁcantly different to pre-immune and greater than 30% cytotoxicity.
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ntibodies for both devils (Fig. 4a and d). But the ELISA detected sig-
iﬁcantly high anti-DFTD antibodies levels at all time points (Fig. 4b
nd e).
.4.2. Cytotoxic responses
TD2 and TD4 had increased cytotoxic responses after the ﬁrst
wo ‘re-immunizations’ (days 14 and 42) with TD2 producing the
tronger response (Fig. 4c and f).
A summary of all responses is shown in Table 2.
. Discussion
Devil facial tumour disease (DFTD) is a fatal and transmissible
ancer. There is no evidence for an immune response against
FTD in wild Tasmanian devils [8,9,30]. This study evaluated the
mmune response against DFTD cells with devils immunized with
nactivated cells in the presence of adjuvants. The endangered
tatus of the Tasmanian devil limited access to animals for research
urposes. Six devils were available of which two devils had to be
sed twice. To maximize the potential to identify responses, all
ix devils were vaccinated. It was not possible to include controls
uch as adjuvant alone and statistical comparison between devils
as not possible. Despite this restriction there was evidence
hat Tasmanian devils can produce humoral and cell-mediated
esponses to DFTD cells.
ELISA was more sensitive than ﬂow cytometry, most likely due
o the ELISA detecting antibodies against total, rather than just cell
urface, antigens. The Cr51 cytotoxicity assays provided evidence
or cytotoxicity following immunizations in most of the devils
ested. As DFTD cells do not express cell surface MHC-I [7] it is
nlikely that cytotoxicity was mediated by CD8+ T cells. There was
o evidence for cytotoxicity in non-immunized devils. This sug-
ests there was no spontaneous NK-cell activity against DFTD cells.
e have previously provided evidence for devil NK cells that could
ediate ADCC. It is unlikely that ADCC occurred in these cultures
s they did not contain antibodies. As there was evidence for cyto-
oxicity one possibility is that the vaccination activated NK cells in
ivo, which killed the DFTD cell in vitro. An alternative explanation
s that interferon- (IFN-) was produced during the 18 h culture.
his could have either activated NK cells or upregulated MHC-I on
he DFTD cells making them targets for CD8+ T cells.
To maximize immunogenicity cells were disrupted by freeze
hawing [31] or by sonication. Of the two devils that were
mmunized with frozen/thawed cells, one produced an antibody
esponse. Evaluation of cytotoxicity was not possible as there was
ot a DFTD cell line available at that time that could be used in
 Cr51 release assay. The evidence of an antibody response was
upported by western blots. Antibodies in the serum from the
evil with the good immune response reacted with a range of
FTD antigens. Some of these are potentially tumor-associated
ntigens. These antigens may  provide more targeted immuno-
ens than whole tumor cells to induce a tumor speciﬁc immune
esponse. This provided the important initial evidence that an
mmune response could be generated against DFTD proteins.
fforts to improve the response were performed by immunizing
wo devils with sonicated cells in the presence of CpG. Both devils
roduced good antibody and cytotoxic responses. Potentially,
pG in association with the disruption of DFTD tumor cells to
xpose multiple antigens may  provide additional stimulatory
ignals. The effects of CpG on marsupials are unknown, but we
ave evidence for functional TLR9 expression on devil leukocytes
Patchett unpublished observations).Targeting the devil’s immune response to cell surface antigens in
rder to improve efﬁcacy may  require whole cells, rather than cell
ragments. Our previous study showed that mice immunized with
ive DFTD cells elicited a strong response [16]. The risk of tumor (2015) 3016–3025
development in devils immunized with live cells was avoided by
irradiating the DFTD cells. Our earlier experience with two dev-
ils immunized with irradiated DFTD cells did not provide evidence
for antibody or cytotoxic responses [15]. This is potentially due to
a lack of genetic diversity among Tasmanian devils and the fail-
ure of DFTD cells to express MHC  antigens [6,7,32]. In the current
experiments all four devils that received irradiated cells devel-
oped cytotoxic responses and three of them developed antibody
responses. Inclusion of CpG distinguishes them from our previ-
ous study. This indicates that the inclusion of TLR9 ligands that
activate innate immune cells [33] may  provide the stimulus to
break ‘immunological ignorance’. The two  devils that were used
twice received sonicated cells and CpG after previously receiv-
ing irradiated or frozen/thawed cells. This delayed ‘boost’ may
have increased the response, as marsupials tend to develop slower
immune responses [34,35].
A potential vaccination strategy that incorporates all of the
above may  provide stronger and more consistent responses. DFTD
cells could be disrupted to increase immunogenicity, CpG or other
TLR agonists would promote the response via innate immune cells,
multiple immunizations followed by a boost. Frozen/thawed, or
sonicated, cells could initially direct the immune response toward
cytoplasmic antigens and potentially expose additional stimulatory
molecules such as heat shock proteins [36]. High-dose -irradiation
is useful for inducing cell death for vaccination [37]. This would
largely preserve the ultrastructure of the tumor cells to target
immune responses against extracellular proteins.
Support for the induction of a protective immune response
against DFTD was  provided when one of the two  devils challenged
with live DFTD cells did not develop the tumor. Both devils received
25,000 strain 2 DFTD cells at each injection site. This provided a
dose between the low number of cells that potentially would be
transmitted through biting and large enough dose for tumor estab-
lishment. As TD1 developed tumors and TD2 develop a tumor on
the second challenge, it was  apparent that 25,000 cells were sufﬁ-
cient. Protection against tumor development is the most deﬁnitive
test for effectiveness of anti-DFTD responses. The devil that did not
develop DFTD at ﬁrst challenge was the one that showed increased
anti-DFTD antibody responses. The boost this devil received 70 days
prior to the ﬁrst challenge may  have provided additional protec-
tion, compared to non-boosted TD1, suggesting that the protection
was not long-term. This is supported by the second challenge for
TD2, which occurred with strain 3, 37 weeks (259 days) after the
last immunization. This resulted in tumor development at both
injection sites 22 weeks (154 days) later. As the tumors developed
simultaneously and were identiﬁed as strain 3, it is unlikely that
the tumor that developed on the right side was  latent or modi-
ﬁed tumor growth from the ﬁrst challenge, more than one year
previously. Although the challenge was with strain 3 and the immu-
nization with strain 2, the antibodies reacted equally well to both
strains and would be equally protective.
A similar length of protection induced in wild devils may  allow
them to resist DFTD during, for example, the breeding season.
This season extends for a period of 3–4 weeks [38] and aggres-
sive displays of mating behavior during this time accounts for a
high proportion of penetrating bite wounds capable of transmit-
ting DFTD [39]. Use of a DFTD vaccine at this time would have the
potential to increase the number of devils successfully breeding
and fully weaning their young.
Ethically, it was  not possible to challenge all devils as the
ﬁrst two  challenged devils both developed tumors. It will remain
unknown if the responses in any of the other devils would have
translated to protection. Despite the evidence for short-term
protection in one devil, a more robust immunization regime
that produces consistent responses is required, prior to further
challenges. Such approaches would include upregulating MHC-I
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n the DFTD cells prior to immunization, modifying the adjuvant
o activate toll like receptors, identiﬁcation and incorporation of
FTD tumor-associated antigens.
The ﬁndings presented above reﬂect the challenges working
ith an endangered species. The small sample size makes it difﬁcult
o control for age and gender. The lack of speciﬁc Tasmanian devil
eagents and assays routinely used in mouse and human immunol-
gy was also limiting. Despite these we provide credible evidence
hat under the right conditions an immune response to DFTD cells
an be generated. This offers the ﬁrst substantial advance toward a
accine.
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